1. Sung, H, Ferlay, J, Siegel, RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.
Google Scholar | Crossref | Medline2. Ryan, DP, Hong, TS, Bardeesy, N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 1039–1049.
Google Scholar | Crossref | Medline | ISI3. Gurusamy, KS, Kumar, S, Davidson, BR, et al. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev 2014; 2: CD010244.
Google Scholar4. Moore, MJ, Goldstein, D, Hamm, J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960–1966.
Google Scholar | Crossref | Medline | ISI5. Conroy, T, Desseigne, F, Ychou, M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
Google Scholar | Crossref | Medline | ISI6. Von Hoff, DD, Ervin, T, Arena, FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
Google Scholar | Crossref | Medline | ISI7. Ueno, H, Ioka, T, Ikeda, M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640–1648.
Google Scholar | Crossref | Medline | ISI8. Walker, EJ, Ko, AH. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol 2014; 20: 2224–2236.
Google Scholar | Crossref | Medline9. Chou, WC, Chen, YY, Hung, CY, et al. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2016. Cancer Manag Res 2019; 11: 2119–2127.
Google Scholar | Crossref | Medline10. Lai, HL, Chen, YY, Lu, CH, et al. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: a 7-year multicenter observational cohort study in Taiwan. Cancer Med 2019; 8: 2085–2094.
Google Scholar | Crossref | Medline11. Pelzer, U, Schwaner, I, Stieler, J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676–1681.
Google Scholar | Crossref | Medline | ISI12. Oettle, H, Riess, H, Stieler, JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423–2429.
Google Scholar | Crossref | Medline | ISI13. Gill, S, Ko, YJ, Cripps, C, et al. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016; 34: 3914–3920.
Google Scholar | Crossref | Medline | ISI14. Ioka, T, Ueno, M, Ueno, H, et al. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer 2019; 106: 78–88.
Google Scholar | Crossref | Medline15. Wang-Gillam, A, Li, CP, Bodoky, G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545–557.
Google Scholar | Crossref | Medline | ISI16. Kieler, M, Unseld, M, Bianconi, D, et al. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncol 2019; 11: 1758835919853196.
Google Scholar | SAGE Journals17. Barzi, A, Miksad, R, Surinach, A, et al. Real-world dosing patterns and outcomes of patients with metastatic pancreatic cancer treated with a liposomal irinotecan regimen in the United States. Pancreas 2020; 49: 193–200.
Google Scholar | Crossref | Medline18. Kasi, A, McGinnis, T, Naik, G, et al. Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. J Gastrointest Oncol 2021; 12: 464–473.
Google Scholar | Crossref | Medline19. Yoo, C, Im, HS, Kim, KP, et al. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Ther Adv Med Oncol 2019; 11: 1758835919871126.
Google Scholar | SAGE Journals20. Glassman, DC, Palmaira, RL, Covington, CM, et al. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer 2018; 18: 693.
Google Scholar | Crossref | Medline21. Su, YY, Chiang, NJ, Tsai, HJ, et al. The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort. Sci Rep 2020; 10: 7420.
Google Scholar | Crossref | Medline22. Park, HS, Kang, B, Chon, HJ, et al. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open 2021; 6: 100049.
Google Scholar | Crossref | Medline23. Bang, K, Cheon, J, Jeong, JH, et al. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. Ther Adv Med Oncol 2021; 13: 17588359211003053.
Google Scholar | SAGE Journals24. Yu, SM, Lu, CH, Liu, KH, et al. External validation of the Besançon nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: a multi-institute experience in Taiwan. Pancreatology 2020; 20: 116–124.
Google Scholar | Crossref | Medline25. Hsu, CC, Liu, KH, Chang, PH, et al. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. J Gastroenterol Hepatol 2020; 35: 1694–1703.
Google Scholar | Crossref | Medline26. Bang, YJ, Li, CP, Lee, KH, et al. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study. Cancer Sci 2020; 111: 513–527.
Google Scholar | Crossref | Medline27. Chen, LT, Macarulla, T, Blanc, JF, et al. Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer. Cancers 2019; 11: 1068.
Google Scholar | Crossref28. Chen, LT, Macarulla, T, Blanc, JF, et al. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): a post hoc analysis of NAPOLI-1. Pancreatology 2021; 21: 192–199.
Google Scholar | Crossref | Medline29. Tossey, JC, Reardon, J, VanDeusen, JB, et al. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Med Oncol 2019; 36: 87.
Google Scholar | Crossref | Medline